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Abstract
Shifting the malaria priorities from a paradigm of control and elimination to a goal of global 
eradication calls for renewed attention to the interruption of malaria transmission. Sustained 
progress toward eradication will require both improved understanding of infectious reservoirs and 
efficient development of novel transmission-blocking interventions, such as rapidly acting and 
highly efficacious therapeutics and vaccines. Here, we review the direct skin feeding assay (DSF), 
which has been proposed as a valuable tool for measuring the in natura transmission of malaria 
parasites from human hosts to mosquito vectors across heterogeneous populations. To capture the 
methodological breadth of this assay’s use, we first systematically review and qualitatively 
synthesize previously published investigations using DSFs to study malaria transmission in 
humans. Then, using a recent Phase 1 trial in Mali of the Pfs25H-EPA/Alhydrogel® vaccine 
candidate (NCT01867463) designed to interrupt Plasmodium falciparum transmission as a case 
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study, we describe the potential opportunities and current limitations of utilizing the endpoints 
measured by DSF in making early clinical decisions for individually randomized transmission-
interrupting intervention candidates. Using simulations based on the data collected in the clinical 
trial, we demonstrate that the capacity of the DSF to serve as an evaluative tool is limited by the 
statistical power constraints of the “effective sample size” (i.e. the number of subjects that are 
capable of transmitting at the time of feeding). Altogether, our findings suggest DSFs have great 
potential utility for assessing the public health impacts of emerging antimalarial tools, but 
additional research is needed to address issues of scalability and to establish correlation with 
community-wide clinical endpoints as well as complementary in vitro measures, such as standard 
membrane feeding assays.
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1. Introduction
Progress toward global malaria eradication will be expedited through the careful integration 
of established malaria elimination strategies with novel transmission-interrupting 
interventions operating across the host, parasite, and vector levels [1, 2]. As highly cost-
effective public health tools with lasting effects on populations, “vaccines that interrupt 
malaria transmission” (VIMTs) are likely to be central to future elimination efforts [1]. 
VIMTs include classical transmission-blocking vaccines that can arrest the sporogonic 
development of the parasite inside the mosquito as well as highly effective pre-erythrocytic 
vaccines and blood-stage vaccines that may decrease the size of the infectious reservoir by 
reducing gametocyte carriage. VIMTs in development will achieve the “minimally 
acceptable target” of expected efficacy if the vaccine, in combination with existing malaria 
elimination tools, maintains Re (i.e. the number of subsequent infections arising from each 
infected human in a population made up of both susceptible and non-susceptible hosts) 
below one for at least one year in a previously malaria-endemic region [1]. Although the 
concept of transmission-interrupting interventions is not new (e.g. indoor residual spraying 
is a highly effective method for decreasing transmission by shortening mosquito lifespans 
and reducing population densities), the individual-level randomization that is possible with 
VIMT candidates creates demand for new analytical frameworks. Barring completion of 
costly and complex cluster randomized controlled trials that evaluate measures such as the 
entomological inoculation rate or clinical incidence of malaria within communities [3], 
robust functional assays that provide potential surrogate measures of individuals’ infectivity 
to mosquitoes have been proposed as the best available approaches for evaluating early 
clinical Go/No Go decisions for VIMT candidates in the research pipeline.
At present, standard membrane feeding assays (SMFAs), which have been qualified 
according to the International Conference on Harmonisation guidelines, are considered the 
gold standard for evaluating the transmission-blocking potential of test antibodies ex vivo [4, 
5]. The SMFAs, which evaluate the functionality of test antibodies by offering cultured 
Plasmodium gametocytes combined with fractionated serum or purified immunoglobulin to 
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laboratory-reared, uninfected mosquitoes through an artificial membrane, have been used to 
rank the activity of transmission-blocking vaccine candidates [4, 6, 7]. Whereas SMFAs 
specifically measure antibody activity in relation to reduction in gametocyte transmission to 
mosquitoes, broadly defined VIMTs may also incorporate pre-erythrocytic or blood-stage 
vaccines that require study of human infection. Direct membrane and skin feeding assays 
can enable investigators to evaluate both reductions in malaria infections and the resulting 
interruption in transmission of parasites from human blood to mosquitoes. The direct 
membrane feeding assay (DMFA) is similar in design to the SMFA except that gametocytes 
are derived from the venous blood of infected individuals and better reflect the diversity of 
field populations [8]. First described by R.C. Muirhead-Thomson in 1957 as a method to test 
“the malarial infectivity of the human subjects in a direct manner,” the direct skin feeding 
assay (DSF) measures the prevalence and magnitude of infection in laboratory-reared 
mosquitoes that are contained in cups and allowed to feed directly on the skin of human 
volunteers [9].
While membrane feeding assays will continue to serve as valuable and well-controlled tools 
for assessing the blockade of transmission, methods that examine host-vector interactions 
through direct skin feeds may offer greater scope for investigating the activity of candidate 
VIMTs on in natura transmission. Overall, there is a high concordance between the direct 
membrane and direct skin feeding methods, and DSFs offer additional biological 
advantages. An analysis of 241 paired transmission experiments demonstrated a significant 
positive correlation (Spearman’s rho of 0.36, p<0.0001) between the proportion of 
mosquitoes infected using DMFAs versus DSFs [8]. However, DSFs offer 2-fold higher 
efficiency in terms of the proportion mosquitoes infected than DMFAs and are also more 
robust to human error [8, 10, 11]. In DMFAs, failure to maintain blood samples at a constant 
temperature of 37°C could lead to the premature activation of gametocytes and interfere with 
gametocyte infectiousness and successful parasitic reproduction [12, 13]. Further, DSFs 
better mimic in vivo feeding conditions than DMFAs. By design, membrane feeding assays 
eliminate differences in host attractiveness to mosquitoes and are also incapable of 
simulating the immune response and gametocyte densities and dynamics that occur in host 
microvasculature [14]. Therefore, we ask: Could DSFs be used as a primary evaluative tool 
for early clinical development of vaccines designed to interrupt malaria transmission?
To answer this, we first systematically reviewed published literature in order to understand 
the scope of research questions and experimental approaches used by scientists who have 
employed DSFs to measure malaria transmission. Then, using a recent Phase 1 trial in Mali 
of the Pfs25H-EPA/Alhydrogel® transmission-blocking vaccine candidate as a case study, 
we outline our experiences in a pilot investigation into the use of DSFs for early phase 
clinical trials and provide estimates for the numbers of participants and feeding assays that 
will provide sufficient power to estimate VIMT activity by DSF.
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2. Direct skin feeding assays to measure malaria transmission: A 
systematic review
2.1. Methods
Using PubMed, Web of Science, and EMBASE, we identified studies that used direct 
feeding assays to estimate the transmission of Plasmodium parasites from human hosts to 
mosquito vectors. We searched the databases using keywords related to the assay, parasite, 
and vector and scanned reference lists for additional relevant articles (Table 1). We screened 
records published after 1 January 1985 and before 24 July 2015 and applied no language 
restrictions; studies using non-human subjects were excluded. Study level characteristics 
were extracted using a standardized data extraction form to collect information on: 
geographic location, number of participants, age range, target Plasmodium and Anopheline 
species, number of mosquitoes per cup, number of cups, mosquito age, length and location 
of feed, repeats of feed, and reported measures of human-to-mosquito transmission, 
including oocyst prevalence (i.e. the proportion of mosquitoes with at least one oocyst), 
oocyst intensity (i.e. the number of oocysts per mosquito), and the relative prevalence of 
gametocytemia in the study sample.
2.2. Results
Our database search retrieved 213 records (Figure 1); 7 additional records were identified by 
reference list review. We excluded 129 duplicate records and 60 records by abstract. After 
carefully reviewing the full-text articles for the remaining 31 records, 11 publications were 
selected for inclusion in the systematic review (Table 2). The 11 studies measuring malaria 
transmission in human populations with DSF were undertaken in 7 countries from 4 
continents. The investigations were designed: (i) to compare direct and membrane feeding 
assays [10, 15–19], (ii) to characterize infectious reservoirs [10, 11, 17, 20–22], and/or (iii) 
to investigate transmission-interrupting activity [17, 18, 23]. The studies employed six 
Anopheline species/ sibling species and primarily targeted Plasmodium falciparum and 
vivax; however, infections by P. malariae and P. ovale were also considered in five studies 
[10, 11, 16, 21, 22]. Study samples, which included between 15 and 685 participants, 
represented a wide range of ages (0.8 to 77 years); 7 of the studies restricted the cohorts to 
individuals who were gametocyte positive at the time of feeding. With the exception of the 
study by Alves, et al. (2005) [20], which incorporated polymerase chain reaction (PCR) to 
identify Plasmodium carriers with low parasitemias, gametocytemia was identified 
microscopically in the included studies. There was great variability in the direct feeding 
procedures. Between 1 to 3 cups, containing 20 to 100 starving mosquitoes aged 3 to 6 days 
were applied to the calves, thighs, and arms of the study participants for between 10 and 30 
minutes. Measures of oocyst prevalence and intensity were commonly reported. Differences 
between study groups (e.g. age categories) were most frequently evaluated using non-
parametric approaches [11, 15–17, 19, 21, 22]; however, several studies – and, notably, two 
investigating transmission-interrupting activity – reported qualitative differences alone [18, 
20, 23]. Diallo, et al. (2008) compared mean oocyst prevalence with a student’s t-test [10]. 
Although Beavogui, et al. (2010) reported completing repeated feeds on the same 
participants over time, oocyst prevalence was less than one percent, and neither the 
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longitudinal results nor statistical adjustment for intra-individual correlations were reported 
[23]. Currently, there is no precedent for utilizing DSFs to quantitatively evaluate the activity 
of candidate VIMTs in a clinical trial.
3. Direct skin feeding assays to evaluate VIMT candidates: A case study
Pfs25, a leading transmission-blocking vaccine candidate, is a highly conserved P. 
falciparum surface antigen expressed during the zygote, ookinete, and young oocyst stages 
of the parasitic lifecycle in the mosquito midgut [24, 25]. When chemically conjugated with 
the outer membrane protein complex of Neisseria meningitidis and a mutant, detoxified 
protein from Pseudomonas aeruginosa known as ExoProtein A (EPA), Pfs25 has been 
demonstrated to elicit sustained antibody responses in mice and guinea pigs as well as 
transmission-reducing and blocking activity in an ex vivo SMFA [26, 27]. For an earlier US-
based Phase 1 clinical trial in healthy adults beginning in 2011, the Pfs25H-EPA vaccine 
was formulated with the aluminum-based adjuvant Alhydrogel® and was shown to be both 
safe and immunogenic; results from SMFAs are consistent with transmission-reducing 
activity (Talaat, et al., submitted).
3.1. Study objectives
From 2013 to 2015, a double-blind, comparator-controlled Phase 1 clinical trial of Pfs25H-
EPA/Alhydrogel® vaccine was conducted in Bancoumana, Mali in a sample of healthy, 
malaria-exposed volunteers aged 18 to 45 years (Figure 2). The primary objective was to 
assess the safety and reactogenicity of the Pfs25H-EPA vaccine, and the results will be 
published separately. As a secondary objective, DSFs were performed to compare human-to-
mosquito transmission between the study arms and to explore the effectiveness of the assay 
in terms of mosquito feeding behaviors and survival. This case study focuses on the results 
of DSFs that were performed following the fourth vaccination and will discuss how the 
findings of this feasibility study can inform future use of DSFs for evaluation of VIMTs.
3.2. Ethical approval and informed consent
The protocol used for the case study was approved by the the Faculty of Medicine, 
Pharmacy, and Oto-Stomatology (FMPOS) ethical committee of the University of Bamako, 
Mali, with Federal Wide Assurance #00001769, the NIH institutional review board, and the 
Mali national regulatory authority and was conducted under FDA IND 14781. First, 
community permission was obtained from village elders, family heads, and community 
associations. Then, before enrollment, individuals were provided with a written informed 
consent form, which was literally translated into French, orally translated into local 
languages, and independently verified for understanding by a witness external to the study 
team. No subject was permitted to undergo more than 12 DSFs within a 12 month study 
period. Volunteers were carefully monitored for adverse events. Prompt care was provided to 
sick participants per standard of care, including treatment of symptomatic malaria in 
accordance with Malian Ministry of Health protocols. Blood smear results were evaluated 
during regular study visits and unscheduled study visits as clinically indicated.
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3.3. Study sample
Of the 100 individuals in the high dose group (receiving either 47 µg Pfs25H-EPA/
Alhydrogel®; n=50 or Euvax/ Hepatitis B followed by Menactra in year 2), 82 volunteers 
(including 42 Pfs25H-EPA/Alhydrogel® and 40 comparators) completed four vaccinations 
(reasons for dropout included: 10 consent withdrawals, 4 losses to follow-up, 2 pregnancies, 
1 relocation, and 1 incarceration). Of the 82 vaccinated individuals, 79 volunteers (including 
41 Pfs25H-EPA/Alhydrogel® and 38 comparators) completed ≥1 DSF following the fourth 
vaccination for a total of 467 DSFs completed (reasons for dropout included: 2 consent 
withdrawals and 1 adverse event).
3.4. DSF procedure
To replicate in natura conditions, laboratory colonies of Anopheles coluzzii were established 
from wild gravid females and reared under controlled conditions in order to minimize 
microbiota contamination and the introduction of adventitious pathogens; mosquitoes from 
the 105th to 109th generations were used for the DSF experiments. In the insectary, 
mosquitoes were maintained on fish food and water in a standardized environment with 
temperature of 25±2° C, humidity of 70±10%, and photoperiodicity of 12 hours. For 
breeding, female mosquitoes were fed on human blood donated by consented individuals 
queried and monitored for fever or other illnesses. All samples of donated human blood that 
were used for colony maintenance and random samples of mosquitoes from the colony were 
regularly monitored by PCR for evidence of Rift Valley Fever. At the age of 3 to 6 days, 
mosquitoes were collected and transferred to small paper cups. Trained project nurses 
applied two cups, containing 30 female mosquitoes each, for 15 minutes directly to the skin 
of the calves of all participants. The gametocyte status of participants at the time of feeding 
was quantified by microscopic examination of Giemsa-stained bloodsmear until 1000 white 
blood cells had been counted. Duplicate bloodsmears were prepared and read, and in cases 
of discordant results (i.e., one positive, one negative), a third bloodsmear was evaluated to 
draw a final inference. Study participants were provided with anti-histamine cream 
following exposure. Engorged mosquitoes were maintained in the feeding cups for an 
additional 7–8 days. Experienced laboratory technicians dissected surviving mosquitoes in 
saline solution. Midguts were stained with mercurochrome, and oocysts were counted by 
microscopy.
3.5. Endpoints of the DSFs
Table 3 summarizes the endpoints produced by the DSFs. 3% (n=14 experiments) of the 
DSFs in the case study resulted in at least one positive mosquito infection (i.e. a feed where 
≥1 mosquito that survived to dissection had an oocyst). Notably, 5 of these 14 experiments 
were performed on volunteers who were gametocyte-negative by microscopy at the time of 
feeding.
At each administration, the DSFs produced three population-wide measures of transmission: 
oocyst prevalence, oocyst intensity, and host infectiousness. Oocyst prevalence was low; 
overall, 0.4% of the 17,128 dissected, engorged mosquitoes had ≥1 oocyst. Further, oocyst 
prevalence was approximately 15% within the subgroup of DSF experiments where at least 
one mosquito became infected (n=14 experiments, n=560 dissected mosquitoes). Although 
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the median oocyst intensity was 0 overall, the median oocyst intensity was 1 (range: 1 to 7) 
within the 83 infected mosquitoes. Overall, 14% of the 79 volunteers infected at least one 
mosquito over the duration of follow-up.
The assays also provided some insight into the exploratory objectives of host attractiveness, 
feed intensity, and mosquito survival. Overall, we found that 100% of individuals 
successfully fed mosquitoes during the primary follow-up period. In total, 99% of the 467 
DSF experiments resulted in any engorged mosquitoes. Within the 461 DSF experiments 
where at least one mosquito fed, the median feed intensity was 95% (range: 33 to 100%) and 
the median percentage of engorged mosquitoes that survived to dissection was 68% (range: 
13 to 95%).
3.6. Estimating vaccine activity
Oocyst prevalence was selected as the primary endpoint to estimate the vaccine activity. 
Oocyst prevalence was selected over other DSF endpoints (i.e. oocyst intensity, host 
infectiousness) to reflect the goal of the VIMT to reduce the number of infected mosquitoes 
that may infect another human host. To evaluate the transmission-blocking activity of the 
vaccine, the primary analysis used a binomial GEE regression to estimate a population-
averaged odds ratio, comparing the odds of a mosquito having ≥ 1 oocyst across the study 
arms while accounting for the repeated nature of the DSF measurements (i.e. up to 6 
repeats). As the oocyst prevalence was very low (i.e. 0.4% of mosquitoes had ≥ 1 oocyst), 
the odds of a mosquito having ≥ 1 oocyst provided a robust approximation for the oocyst 
prevalence within each of the study arms. As a sensitivity analysis, a zero-inflated negative 
binomial mixed-effects model that allowed for volunteer-specific random effects and 
provided an offset for DSF experiment-specific mosquito survival was used to compare the 
per DSF experiment difference in the oocyst prevalence across the study arms while 
accounting for the repeated nature of the DSF measurements (i.e. up to 6 repeats), the 
overdispersion of the data, and the high number of zeroes (i.e. in 99.6% of the data). The 
results of the subsidiary analysis did not differ materially from those of the primary analysis. 
The secondary analysis on oocyst intensity (i.e. averaged across all engorged, dissected 
mosquitoes in a given DSF experiment) used a zero-inflated linear mixed-effects model that 
allowed for volunteer-specific random effects to investigate the transmission-reducing 
activity of the vaccine. The tertiary analysis on host infectiousness used a Fisher’s exact test 
to compare the number of infectious volunteers across the study arms.
3.7. Sample size requirements: lessons learned
In this case study, there was insufficient power to adequately evaluate differences between 
the study arms in terms of any of these DSF endpoints due to the low level of host 
infectiousness. To explore different approaches for optimizing the statistical power for future 
experiments, we first simulated data from a beta-binomial model using parameters based on 
the control arm data from this case study and assuming an individual’s infectivity remains 
constant over time, a constant waning of immune duration based on a 6 month half-life, and 
a fixed zero inflation level at the observed 84% or an optimistic test level of 75% (i.e. 
reflecting the percentage of control arm volunteers who never transmitted malaria to a 
mosquito during all DSF repeats). Then, we used a binomial generalized estimating equation 
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with a two-sided alpha of 0.05 for the vaccine indicator to estimate the numbers of 
volunteers, repeats, and mosquitoes that would be necessary to detect an 80% transmission-
blocking activity by a VIMT candidate using oocyst prevalence values measured by DSF.
As shown in Table 4, the current case study with 38 and 41 participants per study arm and 6 
feeds with 2 cups containing a total of 60 mosquitoes had an estimated 12% statistical power 
to detect a transmission-blocking activity of 80% in a binomial GEE model holding the zero 
inflation constant at the observed rate of 84%. Increasing the number of subjects per study 
arm up to 100 would increase the statistical power to 40%. Alternatively, doubling the 
number of feed repeats to 12 would similarly increase the statistical power to 38%, assuming 
50 subjects per arm. In contrast, doubling the number of mosquitoes applied (i.e. while using 
4 cups instead of 2) would have a minimal impact on statistical power. Increasing both the 
sample size to 100 subjects per arm and doubling the number of DSF repeats to 12 would 
raise the statistical power to 80%, a more acceptable threshold for clinical trials; however, 
further studies are needed to determine whether increasing the number of feeds per volunteer 
will increase study attrition. Table 4 also presents statistical power under the same model for 
a 75% zero inflation level (i.e. where 75% of the participants never transmit during all 
DSFs). With this assumption, increasing the number of subjects per study arm up to 100 
would increase the statistical power to 95% and doubling the number of feed repeats to 12 in 
a study with 50 subjects per arm would increase the statistical power to 80%. These results 
underscore the idea that the capacity of the DSF to serve as an evaluative tool for candidate 
VIMTs is limited by the “effective sample size” (i.e. the number of subjects that are capable 
of transmitting at the time of feeding). Assuming similar rates of drop-out during 
immunizations and that the percentage of participants who transmitted during DSFs 
remained at 16% (i.e. a zero inflation of 84%), these simulations suggest we would need a 
total number 220 participants (i.e. with 110 subjects per arm) to achieve the effective sample 
size needed to measure a transmission-blocking activity of 80% using the oocyst prevalence 
measurements for the current case study scenario.
4. Future Research
While DSFs have great potential as tools to quantify the elicitation of transmission-blocking 
activity by candidate VIMTs at the individual level, additional research is needed to address 
the scalability and clinical relevance of these assays.
Questions of scale must first consider how one can adapt and extend successful practices to 
reach an expanding pool of people in varied geographies. The results of the systematic 
review suggest that DSFs offer flexibility in terms of the regionally specific Anopheline-
Plasmodium pairings and acceptability across diverse cultural and demographic contexts. 
Extra consideration will be needed before administration of the DSF to special populations, 
including pregnant women and young children under five, to whom the assay is typically not 
administered. In addition, as the DSF is a rough facsimile of true transmission, further 
research is needed to test whether assay design features, such as the use of 
multigenerational, laboratory-reared mosquitoes, containment to feeding cups, could limit 
the relevance of the assay results to field conditions [28]. Moreover, the active follow-up of 
Brickley et al. Page 8
Vaccine. Author manuscript; available in PMC 2017 November 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
participants could modify the natural progression of the disease and potentially alter the 
density of gametocytes available for transmission.
Scaling up DSFs for the evaluation of VIMTs may also be limited by the low throughput 
nature of the assay. The logistics of maintaining a mosquito colony and conducting feeding 
assays are considerable, and manually dissecting mosquito midguts for oocysts is a labor-
intensive procedure. In the pilot investigation of the case study, DSFs were repeatedly 
administered to all participants regardless of gametocyte status over the course of the 
transmission season with the aim of capturing the infectivity of the entire study sample, 
including individuals with submicroscopic infections. While gametocyte-negative hosts did 
contribute substantively to the absolute numbers of DSF experiments with transmission, the 
relative proportion of DSFs experiments on gametocyte-negative volunteers versus those in 
gametocyte-positive volunteers that resulted in transmission was low. Therefore, there may 
be value in further investigation into whether greater efficiencies could be achieved through 
a two-stage assessment that incorporates information from both gametocyte screening and 
the DSF endpoints of gametocyte-positive individuals. Alternatively, the effective sample 
size could be increased by targeting early stage VIMT trials to regions with exceptionally 
high transmission or to subgroups of the population that act as the main infectious reservoirs 
[16, 29, 30]. Still in development, immunochemistry may enable the quantification of 
parasites from a given cup as a group and, potentially, at an earlier point in the gametocyte to 
oocyst transition [31], and nucleic acid-based methods for oocyst detection in pooled 
mosquito samples might similarly increase automation and throughput.
Although the case study DSF experiments generally performed well in terms of host 
attractiveness and feeding intensity, experimental design parameters could also be further 
optimized to increase the numbers of successful feeds and infections in order to improve the 
sensitivity of the DSF. For example, much remains unknown about the somatic distribution 
of the gametocytes within the human microvasculature, and the specific placement of the 
paper cups on the participant’s body may alter results. It has also been previously 
established that the number of mosquitoes in a container is important for competition; 
further investigations are required to identify the optimal number of mosquitoes per cup for 
maximizing mosquito survivorship [5, 8]. Ultimately, standardization of the DSF and its 
associated analytical methods are needed to reduce variation and improve reproducibility for 
its use in support of regulatory submissions of emerging antimalarial tools.
From a clinical perspective, additional research is needed to validate the correlation between 
the individual DSF endpoints and a community-level effect, such as the incidence of malaria 
infection or clinical disease. In lieu of a large, cluster-randomized trial that simultaneously 
undertakes DSFs and clinical follow-up, smaller scale experiments using known 
transmission-blocking agents, such as primaquine, may provide partial validation of the 
DSF. In addition, mathematical models may facilitate estimation of the VIMT candidate’s 
total effectiveness in a community, including both the direct effects on the vaccinated 
population as well as the herd effects on the remainder of the population, in terms of 
transmission. Commendably, Smith, et al., (2011) have developed a quantitative framework, 
based on the Ross-McDonald method, to explore the effects of malaria vaccines on the Re 
[32]. In the model, vaccine efficacy is defined as “the probability that an infectious host 
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transmits when a mosquito feeds on it,” which could as a proxy for “the reduction of 
transmission in the community” called for by the malERA target product profile [32].
5. Conclusions
Sustained progress toward malaria control, elimination, and eventual eradication will require 
both improved understanding of infectious reservoirs and efficient development of novel 
transmission-blocking interventions, such as vaccines that interrupt malaria transmission. 
Here we demonstrate that DSFs, which measure the infectiousness of individuals living in 
diverse settings using naturally occurring parasite strains under controlled conditions that 
simulate in natura transmission, have great potential utility for assessing emerging 
antimalarial tools, but require considerable logistics and hence will most likely be applied 
when evaluating the most promising new candidates or strategies for malaria elimination.
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Figure 1. Study flow diagram for the literature-based systematic review
The figure is based on the 2009 PRISMA flow diagram template (available from http://
www.prisma-statement.org/statement.htm).
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Figure 2. Simplified study schema for NIAID Protocol 13-I-N109 trial (clinicaltrials.gov 
NCT01867463), a Phase 1 study of the Pfs25H-EPA/Alhydrogel® malaria transmission blocking 
vaccine started in May 2013 at the Malaria Research and Training Center in Bancoumana, Mali
The dashed red rectangle indicates the 6 week period of follow-up contributing to the case 
study data. For the trial, 120 health adults were enrolled in a staggered, dose-escalating 
manner. Volunteers were individually randomized 1:1 to receive either the study vaccine or 
the comparator vaccine(s), Euvax B (LG Life Sciences, Seoul, Korea), a recombinant 
hepatitis B vaccine, and Menactra® (Sanofi Pasteur, Lyon, France), a conjugated, 
polysaccharide vaccine against Neisseria meningitides serogroups A, C, Y, and W-135 
(Figure 2). Twenty subjects (Group 1) received a low dose (16 µg Pfs25H-EPA/
Alhydrogel®; N=10 or Euvax/Hepatitis B; N=10) and 100 subjects (Groups 2 and 3) 
received a high dose (47 µg Pfs25H-EPA/Alhydrogel®; n=50 or Euvax/ Hepatitis B followed 
by Menactra in year 2; n=50). Vaccinations in the low dose group were scheduled at 0 and 2 
months with 12 months of safety follow-up. Vaccinations in the high dose group were 
scheduled at 0, 2, 4, and 16 months. The third vaccination was given in September 2013, and 
during the following six months, DSFs were completed if a subject was found to be parasite/
gametocyte positive in order to establish assay methodologies (these data are not included in 
the transmission-blocking activity estimates). Starting two weeks after the fourth vaccination 
in September 2014, DSFs were performed weekly for six weeks and at least once on all 
enrolled volunteers (n=79). As DSFs were repeatedly administered to all participants 
regardless of gametocyte status over the course of the transmission season, these assays were 
designed to capture the infectivity of the entire study sample, including individuals with 
submicroscopic infections.
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Table 1
Search strategy for the literature-based systematic review.
Database Search Terms
PubMed (direct feed* [tiab] or direct skin feed* [tiab] or feeding assay [tiab] or feed assay [tiab]) & (Vaccine [MeSH] or Malaria 
Vaccines [MeSH] or Malaria [MesH] or Malaria, falciparum [MeSH] or malaria [tiab] or Culicidae [MeSH] or mosquito* 
[tiab] or oocysts [MesH] or oocyst* [tiab])
Web of Science (((“direct feed*” OR “direct skin feed*” OR “feed assay” OR "feeding assay") AND (vaccine* OR malaria OR falciparum 
OR Culicidae OR mosquito* OR oocyst*)))
EMBASE 'direct feed' OR 'direct feeding' OR 'direct skin feed' OR 'direct skin feeding' OR 'feed assay' OR 'feeding assay' AND 
('vaccine'/exp OR 'vaccine' OR vaccine* OR 'malaria vaccine'/exp OR 'malaria vaccine' OR falciparum OR 'culicidae' OR 
'culicidae'/exp OR culicidae OR mosquito* OR oocyst*) AND ([article]/lim OR [article in press]/lim OR [editorial]/lim OR 
[erratum]/lim OR [letter]/lim OR [note]/lim OR [review]/lim OR [short survey]/lim)
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Table 3
Definitions of DSF experimental endpoints.
Objective Metric Measure Name Measure Definition
Primary Transmission-blocking activity Oocyst prevalence Proportion of engorged, dissected mosquitoes with ≥1 oocyst
Secondary Transmission-reducing activity Oocyst intensity Number of oocysts per engorged, dissected mosquito
Tertiary Infectious reservoir Host infectiousness Proportion of volunteers infecting ≥1 mosquito over duration of 
study
Exploratory Mosquito behavior Host attractiveness Proportion of volunteers feeding ≥1 mosquito over duration of 
study
Feed intensity Proportion of engorged mosquitoes per experiment
Mosquito survivorship Proportion of engorged mosquitoes that survived to dissection
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